版本:
中国

BRIEF-Epizyme collaborates with Foundation Medicine for tazemetostat phase 2 clinical trial

Sept 21 Epizyme Inc

* Epizyme establishes collaboration with Foundation Medicine to support tazemetostat phase 2 clinical trial

* Collaboration agreement with Foundation Medicine to support patient identification and enrollment for Epizyme's ongoing phase 2 clinical trial of tazemetostat

* Early clinical data suggest tazemetostat has encouraging clinical activity and favorable safety profile in patients with relapsed,refractory NHL

* Plans to initiate additional clinical trials of tazemetostat in 2016 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐